Processes to produce a common viral vector for gene therapy – adeno-associated virus (AAV) – are in place, but there’s room to improve them. Here we focus on optimizing AAV purification to achieve high overall yields and efficiently remove empty capsids and other impurities.
We developed a purification process for AAV2 and AAV5 serotypes, based on scalable, cost-efficient, and robust filtration and chromatography-based processes. The steps include harvest by cell lysis, clarification, concentration and buffer exchange, affinity capture, and finally anion exchange polishing to reduce empty capsids.
Further, we developed a convenient Biacore™ surface plasmon resonance (SPR) assay for robust and accurate determination of AAV2 titer.
Read this article to see the results.